Small correction about translation (Headline shoul

Small correction about translation (Headline should be):

CytoDyn: Tomorrow it really starts!
News source: Investor publisher | 04/26/2020, 10:05 |
1253 | 0 | 1 Photo: www.anlegerverlag.de11

CytoDyn is currently perhaps the greatest hope in the fight against the pandemic. With the drug Leronlimab, the company has developed a remedy that can cure sick people.

The drug is currently undergoing another clinical trial to confirm its effectiveness.

Tomorrow Monday, CytoDyn will publish further findings.

So it is quite possible that the share will go through the roof tomorrow.

CytoDyn has the best chance of making a breakthrough in the fight against Corona.

If the positive trends in the studies are confirmed, leronlimab should be used all over the world.

A huge sales perspective!

Especially since CytoDyn recently announced a price of $ 1,200 per injection.

In any case, the CytoDyn share price has known only one direction for weeks.

Since March 26, prices have been rising almost continuously. At the end of March there was an explosion from 0.86 to 3.34 euros. The share corrected somewhat in April, but this week CytoDyn is heading for the 3 euro mark again.

Investor publisher: CytoDyn: Tomorrow it really starts! | wallstreet-online.de - Full article at:

https://www.wallstreet-online.de/news/1244657...ichtig-los